Teclistamab,Daratumumab,Pomalidomide,Lenalidomide,Bortezomib,Nirogacestat
Genmab,Janssen,springworks therapeutics,Takeda,bms
['mmsm', 'teclistamab']
although i am super excited about teclistamab combinations in earlier lines of therapy, 6.25% fatal aes 2/2 infection in dara-tec-len is concerning. need to develop new strategies to mitigate infection risk such that greater efficacy is not neutralized by high tox. #ash22 #mmsm 
Hematologist/Cancer Doctor/Clinical Researcher @ColumbiaCancer 
#Myeloma #Amyloidosis
Asst. Prof @ColumbiaMed
Host @BloodCancerTalk
COI: https://t.co/du0rVN9gca